{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:04:00Z","timestamp":1768590240027,"version":"3.49.0"},"reference-count":25,"publisher":"American Society of Consultant Pharmacists","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>Antiresorptive medications, including bisphosphonates and RANK-L inhibitors, are commonly used to treat various skeletal pathologies. One devastating complication associated with these drugs is medication-related osteonecrosis of the jaw (MRONJ). Patients who develop MRONJ suffer immensely from oral lesions that may persist, even with treatment, until their death. The jawbone is known to remodel 5 to 10 times faster than skeletal bone. Dentists are at the forefront in managing the severe maxillofacial repercussions of MRONJ. Because MRONJ risk is relatively low (reportedly 0.7% to 6.7%) it is underappreciated by many clinical specialties. The minimization of MRONJ is further compounded because it may take months or years to develop. To date, dental treatment protocols are based more on expert opinion than concrete scientific evidence. This iatrogenic, intractable illness is discouraging for both the patient and the treating dentist. To promote multidisciplinary understanding and cooperation, a single MRONJ case caused by intravenous pamidronate is presented, along with commentary from a dentist\u2019s perspective. The intent is that these data will increase awareness of MRONJ\u2019s stomatognathic consequences to the physician, who prescribed the causative agent, and the pharmacist, who dispensed it. Collaboration between the dentist, physician, and pharmacist has tremendous potential to improve treatment strategies and, ultimately, optimize patient care.<\/jats:p>","DOI":"10.4140\/tcp.n.2022.458","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T04:34:49Z","timestamp":1661834089000},"page":"458-467","source":"Crossref","is-referenced-by-count":6,"title":["A Dentist\u2019s Perspective on the Need for Interdisciplinary Collaboration to Reduce Medication-Related Osteonecrosis of the Jaw"],"prefix":"10.4140","volume":"37","author":[{"given":"Alec","family":"Griffin","sequence":"first","affiliation":[{"name":"1 George E. Wahlen Department of Veterans Affairs Medical Center, Research and Development, Salt Lake City, Utah."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Brain","sequence":"additional","affiliation":[{"name":"2 George E. Wahlen Department of Veterans Affairs Medical Center, Dental Clinic, Salt Lake City Dental Clinic, Salt Lake City, Utah."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colby","family":"Hancock","sequence":"additional","affiliation":[{"name":"5 Utah Cancer Specialists, Salt Lake City, Utah."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujee","family":"Jeyapalina","sequence":"additional","affiliation":[{"name":"1 George E. Wahlen Department of Veterans Affairs Medical Center, Research and Development, Salt Lake City, Utah."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update.","volume":"72","year":"2014","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects.","volume":"48","year":"2011","journal-title":"Bone."},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice.","volume":"83","year":"2008","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4081\/reumatismo.2017.983","article-title":"Drug-induced osteonecrosis of the jaw: the state of the art.","volume":"69","year":"2017","journal-title":"Reumatismo."},{"key":"ref5","year":"2021","journal-title":"Osteonecrosis of the Jaws: Oral and Intravenous Bisphosphonates and Subcutaneous Denosumab. VUMEDI. Published 2014. Accessed June 9"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.11607\/jomi.te61","article-title":"A decade of bisphosphonate bone complications: what it has taught us about bone physiology.","volume":"29","year":"2014","journal-title":"Int J Oral Maxillofac Implants."},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.","volume":"102","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","article-title":"Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.","volume":"25","year":"2005","journal-title":"Clin Drug Invest."},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2167","article-title":"Role of RANKL inhibition in osteoporosis.","volume":"9","year":"2007","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/17455057.2.4.517","article-title":"Denosumab: a promising drug for the prevention and treatment of osteoporosis.","volume":"2","year":"2006","journal-title":"Womens Health (Lond)."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.15605\/jafes.033.02.13","article-title":"Osteonecrosis of the jaw and bilateral atypical femoral fracture both occurring during treatment for osteoporosis: a case report.","volume":"33","year":"2018","journal-title":"J ASEAN Fed Endocr Soc."},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1210\/jc.2011-2332","article-title":"Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"24","key":"ref13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment\u2014 the fracture intervention trial long-term extension (FLEX): a randomized trial.","volume":"296","year":"2006","journal-title":"JAMA."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/ijpvm.IJPVM_33_19","article-title":"Therapeutic dimensions of bisphosphonates: a clinical update.","volume":"11","year":"2020","journal-title":"Int J Prev Med."},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.11607\/jomi.te40","article-title":"The deception and fallacies of sponsored randomized prospective double-blinded clinical trials: the bisphosphonate research example.","volume":"29","year":"2014","journal-title":"Int J Oral Maxillofac Implants."},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.","volume":"16","year":"2011","journal-title":"Oncologist."},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.identj.2020.12.005","article-title":"Differences in the knowledge and experience of physicians and dentists about medication-related osteonecrosis of the jaw in osteoporotic patients.","volume":"71","year":"2021","journal-title":"Int Dent J."},{"key":"ref18","first-page":"a930","article-title":"Denosumab-associated osteonecrosis of the jaw; a case series and literature review.","volume":"9","year":"2016","journal-title":"BJMP."},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5125\/jkaoms.2020.46.1.19","article-title":"The effects of pentoxifylline and tocopherol in jaw osteomyelitis.","volume":"46","year":"2020","journal-title":"J Korean Assoc Oral Maxillofac Surg."},{"key":"ref20","article-title":"Positive impact of platelet-rich plasma and platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid.","year":"2019","journal-title":"Sci Rep Uk."},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.joms.2003.12.003","article-title":"Platelet-rich plasma: evidence to support its use.","volume":"62","year":"2004","journal-title":"J Oral Maxil Surg."},{"key":"ref22","volume-title":"FDA Drug Safety Communication: Safety Update for Osteoporosis Drugs, Bisphosphonates, and Atypical Fractures","year":"2018"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12663-019-01211-2","article-title":"Bisphosphonate-induced osteonecrosis of the jaws (BIONJ).","volume":"19","year":"2020","journal-title":"J Maxillofac Oral Surg."},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.","volume":"60","year":"2019","journal-title":"Singap Med J."},{"key":"ref25","volume-title":"Current Therapy in Oral and Maxillofacial Surgery","year":"2012"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2022\/00000037\/00000009\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T20:11:10Z","timestamp":1727899870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2022.458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["2639-9636(20220901)37:9L.458;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2022.458","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}